Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New therapies under development promise improved relief for Non-Hodgkin’s Lymphoma cancer patients

29.10.2003


Technical Insights’ Genetic Technology Alert



Biotech companies and researchers across the world are focusing on the development of new therapies for the treatment of Non-Hodgkin’s Lymphoma (NHL) cancer, a lethal and malignant disease that is spreading at an alarming rate.

"About 300,000 people in the United States are affected by NHL and it causes about 23,000 deaths each year in the U.S. alone," says Technical Insights Analyst Al Hester. "This has created a greater need for advanced NHL therapies."


Rituxan (rituximab), from the California-based IDEC Pharmaceuticals, was the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of a particular form of NHL. It has found widespread market acceptance and its sales surpassed the $1 billion per year mark.

The efficaciousness of the drug challenges developers of new therapies to discover treatment with some distinct advantages to differentiate their products and provide better relief for patients.

"The need for improved lymphoma treatments has by no means disappeared and a large market awaits developers of successful new products," says Hester.

Sensing the potential, many biotech firms have joined the global race for developing new NHL therapies despite being confronted by high production costs.

"Most of the new lymphoma therapies under development are monoclonal antibodies," says Hester. "These antibodies are high-priced proteins and, therefore, they are expensive to manufacture and also inconvenient to administer to the patients."

However, they can be generated to target specific therapeutic molecules. Biotech firms, betting on monoclonals for developing advanced lymphoma therapeutics, are targeting CD20 antigen that may be found on normal, as well as abnormal B cells. In addition, other antigens such as CD4, CD22, and CD30 are being targeted.

Some biotech firms are also trying gene therapy and vaccines to treat patients. These treatment methods could be advantageous as they avoid some of the side effects often associated with monoclonal antibodies, as well as the difficulties in gaining FDA approval.

The studies conducted by Genetic Technology Alert has revealed that the therapies market is capable of generating revenues worth more than $5 billion per year, as there is a steady increase in patient base.

New analysis by Technical Insights, a business unit of Frost & Sullivan (http://www.Technical-Insights.frost.com), featured in the Genetic Technology Alert, presents a critical insight of various therapies that are under research and different phases of clinical trials. The research also discusses the different approaches to treatment and highlights the prime qualities of these potential drugs. This is likely to provide a bird’s eye view of the emerging market opportunities.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and reports.

This analysis is part of the Genetic Technology Alert, which includes market insights on new developments in genetic technologies for the industry. Copies of the alert and interviews are available to the press.

Frost & Sullivan, an international growth consultancy, has been supporting clients’ expansion for more than four decades. Our market expertise covers a broad spectrum of industries, while our portfolio of advisory competencies include custom strategic consulting, market intelligence and management training. Our mission is to forge partnerships with our clients’ management teams to deliver market insights and to create value and drive growth through innovative approaches. Frost & Sullivan’s network of consultants, industry experts, corporate trainers and support staff, spans the globe with offices in every major country.

Julia Paulson | EurekAlert!
Further information:
http://www.ti.frost.com/

More articles from Health and Medicine:

nachricht Spanish scientists create a 3-D bioprinter to print human skin
24.01.2017 | Carlos III University of Madrid

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists spin artificial silk from whey protein

X-ray study throws light on key process for production

A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Breaking the optical bandwidth record of stable pulsed lasers

24.01.2017 | Physics and Astronomy

Choreographing the microRNA-target dance

24.01.2017 | Life Sciences

Spanish scientists create a 3-D bioprinter to print human skin

24.01.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>